(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
Active, not recruiting · NCT03837821 · Registry updated 2025-11-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| (CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder cancer, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Early phase 1 | 2025-11-18 | NCT03837821 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eli Lilly and Company | 370 |
| Weill Medical College of Cornell University | 276 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| UT Southwestern Medical Center - Simmons Comprehensive Cancer Center | Dallas | United States | 1 |
| Weill Cornell Medicine | New York | United States | 122 |